Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.

MLA

Janssen, Q. P., et al. “Total Neoadjuvant FOLFIRINOX versus Neoadjuvant Gemcitabine-Based Chemoradiotherapy and Adjuvant Gemcitabine for Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC-2 Trial): Study Protocol for a Nationwide Multicenter Randomized Controlled Trial.” BMC Cancer, vol. 21, no. 1, Mar. 2021, pp. 1–8. EBSCOhost, https://doi.org/10.1186/s12885-021-08031-z.

APA

Janssen, Q. P., van Dam, J. L., Bonsing, B. A., Bos, H., Bosscha, K. P., Coene, P. P. L. O., van Eijck, C. H. J., de Hingh, I. H. J. T., Karsten, T. M., van der Kolk, M. B., Patijn, G. A., Liem, M. S. L., van Santvoort, H. C., Loosveld, O. J. L., de Vos-Geelen, J., Zonderhuis, B. M., Homs, M. Y. V., van Tienhoven, G., Besselink, M. G., & Wilmink, J. W. (2021). Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer, 21(1), 1–8. https://doi.org/10.1186/s12885-021-08031-z

Chicago

Janssen, Q. P., J. L. van Dam, B. A. Bonsing, H. Bos, K. P. Bosscha, P. P. L. O. Coene, C. H. J. van Eijck, et al. 2021. “Total Neoadjuvant FOLFIRINOX versus Neoadjuvant Gemcitabine-Based Chemoradiotherapy and Adjuvant Gemcitabine for Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC-2 Trial): Study Protocol for a Nationwide Multicenter Randomized Controlled Trial.” BMC Cancer 21 (1): 1–8. doi:10.1186/s12885-021-08031-z.